New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
California startup Protuoso raises $9.5m for “mix-and-match” drug platform - Pharmaceutical Technology
EU and US advisers split over AstraZeneca breast cancer drug
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
CellCentric has reeled in a $220 million Series D to help it address multiple myeloma patients who have exhausted all other…
